Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

Catalent is an attractive buyout target for Novo Holdings, which owns 77% of the voting shares in Novo Nordisk. The deal could boost availability of the drugs because Catalent is the main supplier ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.